| ²é¿´: 216 | »Ø¸´: 5 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
lyh447lyh447ÎÞ³æ (³õÈëÎÄ̳)
|
[½»Á÷]
DGKzeta»ùÒò·½Ã漸¶Î+2009Äê12ÔÂ28ÈÕ
|
||
|
Plasmids and DNA Constructs¡ªRat DGK-IV cDNA was a generous gift of K. Goto (Yamagata University School of Medicine, Sendai, Japan). pSREflagDGKIV was excised with EcoRI, and the 3.4-kb fragment encoding the DGK-IV cDNA was subcloned in the pcDNA3Myc vector (pCDNAMycDGK-IV). For expression experiments, all constructs were subcloned in the pEGFPBos vector in the GFP C terminus. For the MCA construct, pCDNA3MycDGKIV was digested with BstXI/BglII, and the 2.2-kb fragment was subcloned in pEGFPBos. To generate the ankyrin domains deletion (ANK), pCMV3MycDGKIV was SacI-digested, blunted, KpnI-digested, and subcloned in pEGFPBos digested with KpnI/SmaI. Site-directed mutagenesis was performed using the QuikChange site-directed mutagenesis kit (Stratagene). To generate the kinase-dead version of the enzyme, Gly-354 was replaced with Asp as described (25). We designed two mutations in the MARCKS homology domain; in the first we replaced Ser-259, Ser-266, Ser-271, and Ser-272 with Ala (mutant Ser 3 Ala), and in the second the same residues were replaced with Asp (mutant Ser 3 Asp). To mutate the CRDs, the first conserved His in each of the two CRDs of the protein, His-98 or His-173, were replaced with Gly either in the wild type protein or in the Ser 3 Asp mutant. The C-terminal domain (CT) construct, including the four ankyrin repeats and the PDZ-binding motif, was generated by PCR with appropriate primers, which included two restriction sites, SalI and XbaI. The PCR product was subcloned in the pGEM-T easy vector (Promega) and then excised with SalI/XbaI to be subcloned in the expression vector pEFBosCX-HA, which was previously digested with SalI/XbaI. Cell Lines and Transient Transfections¡ªCOS-7 cells were maintained in Dulbecco¡¯s modified Eagle¡¯s medium supplemented with 10% fetal bovine serum and 2 mM glutamine. For transfection, 60¨C80% confluent cells were transfected with LipofectAMINE (Invitrogen) according to the manufacturer¡¯s instructions. After 24 h cells were harvested, and each sample was divided into two pellets for immunoblot and a DAG activity assay. The J-HM1-2.2 cell line was generated by stable transfection of the human muscarinic subtype 1 receptor in the Jurkat cell line (29). Cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum and 2 mM glutamine. Cells (1.2 107) were transfected by electroporation with 20 g of DNA using a Gene Pulser (Bio-Rad) at 270 V and a capacitance of 975 microfarads. Cells were immediately transferred to 30 ml of growth medium and assayed 24 h later. Ï£Íû´ó¼ÒÖ§³Ö£¬ÎÒ²»Ì«¶®»ùÒò·½Ã棬ÎÒÏë×ödgk»ùÒòתȾ£¬µ«Õâ·½ÃæÎÒ²»»á£¡£¡£¡Ð»Ð»´ó¼ÒÎÒ£¬ÎÒ°ÉÈ«²¿Äóö£¬Ï£Íû´ó¼Ò°ï°ï棡£¡£¡Íò·Ö¸Ðл£¡£¡£¡ |
» ²ÂÄãϲ»¶
323·Ö£¨¼ÆËã»úÊÓ¾õºÍ´óÄ£ÐÍÏîÄ¿£©ÄÜÖ±½ÓÉÏÊÖ
ÒѾÓÐ3È˻ظ´
¸´ÊÔµ÷¼Á
ÒѾÓÐ3È˻ظ´
311·Ö 22408 Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
320·ÖÈ˹¤ÖÇÄܵ÷¼Á
ÒѾÓÐ7È˻ظ´
Ò»Ö¾Ô¸Ö£´ó0705Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
0703»¯Ñ§
ÒѾÓÐ10È˻ظ´
301Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
306·Ö²ÄÁÏÓ뻯¹¤Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ11È˻ظ´
324Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
sophia622
ľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1794.4
- ºì»¨: 1
- Ìû×Ó: 207
- ÔÚÏß: 28.6Сʱ
- ³æºÅ: 490611
- ×¢²á: 2008-01-03
- ÐÔ±ð: MM
- רҵ: ÉúÎﻯѧ
µÚÒ»¶Î
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
lyh447lyh447(½ð±Ò+16,VIP+0):ÌØ±ð¸Ðл£¡£¡£¡ 12-27 00:08
lyh447lyh447(½ð±Ò+16,VIP+0):ÌØ±ð¸Ðл£¡£¡£¡ 12-27 00:08
| ÖÊÁ£DNA¹¹½¨¡ª¡ªÊóDGK-IVµÄcDNAÓÉK.GotoÓÑÇéÌṩ£¨Yamagata University School of Medicine, Sendai, Japan£©pSREflagDgkIVÓÃEcoRIÇи±àÂëDGK-IV cDNAµÄ3.4kbµÄƬ¶ÎÑǿˡµ½pcDNA3MycÔØÌå(pCDNAMycDGK-IV£©¡£ÎªÁ˱í´ïʵÑ飬ËùÓй¹Ôì±»Ñǿˡµ½pEGFPBosÔØÌåGFPµ°°×µÄCÄ©¶ËÉÏ£»ÎªÁËMCAµÄ¹¹½¨£¬ÓÃBstXI/BglIIÏû»¯pCDNA3MycDGKIV£¬Ïû»¯²úÉúµÄ2.2kbµÄƬ¶ÎÑǿˡµ½pEGFPBosÉÏ¡£ÎªÁ˲úÉú궨µ°°×½á¹¹Óòɾ³ý£¨( ANK£©pCMV3MycDGKIVÓÃSacI¡¢KpnI½øÐÐ˫øÇУ¬²¢ÇÒÑǿˡµ½ÓÃKpnI/SmaIÏû»¯µÄpEGFPBosÔØÌåÉÏ¡£ÓÃQuikChange site-directed mutagenesisÊÔ¼ÁºÐ(Stratagene)¼ì²âλµãÖ±½ÓµÄÍ»±ä¡£ÎªÁ˲úÉúøµÄ¼¤Ã¸Ê§»î£¬Gly-354±»AspÌæ´ú£¨25£©¡£ÎÒÃÇÉè¼ÆÁË2¸öÍ»±äÔÚMARCKSͬԴ½á¹¹Óò£¬µÚÒ»¸öλµãÊÇSer-259, Ser-266, Ser-271ºÍSer-272Í»±ä³ÉAla£¨Í»±äSer 3 Asp)£¬µÚ¶þ¸öÏàͬµÄ²Ð»ù±»AspÈ¡´ú£¨Í»±äSer 3 Asp£©¡£ÎªÁËÍ»±äCRDsµ°°×Á½¸öCRDsµÄµÚÒ»¸ö±£ÊصÄHis£ºHis-98 »òHis-173ÔÚÒ°ÉúÐÍÖб»GlyÌæ´ú£¬ÔÚÍ»±äÐÍÖб»Ser 3 Asp¡£CÄ©¶Ë½á¹¹Óò¹¹½¨°üÀ¨Ãª¶¨µ°°×ÖØ¸´ÐòÁкÍPDZ½áºÏ»ùÐò£¬ÓúÏÊʵÄÓÐSalI ºÍXbaIøÇÐλµãµÄÒýÎï½øÐÐPCRÀ©ÔöµÄ·½·¨²úÉú¡£PCRµÄ²úÎïÑǿˡµ½pGEM-T easy£¨Promega£©ÔØÌåÖÐÈ»ºóÓÃSalI/XbaIøÇУ¬È»ºóÑǿˡµ½ÓÃSalI/XbaIøÇеıí´ïÔØÌåpEFBosCX-HAÉÏ¡£ |
2Â¥2009-12-26 21:08:07
sophia622
ľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1794.4
- ºì»¨: 1
- Ìû×Ó: 207
- ÔÚÏß: 28.6Сʱ
- ³æºÅ: 490611
- ×¢²á: 2008-01-03
- ÐÔ±ð: MM
- רҵ: ÉúÎﻯѧ
µÚ¶þ¶Î
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
lyh447lyh447(½ð±Ò+10,VIP+0):·Ç³£¸Ðл£¡£¡£¡ 12-27 00:08
zap65535(½ð±Ò+3,VIP+0):ÖúÈËΪÀÖ 12-27 01:58
lyh447lyh447(½ð±Ò+10,VIP+0):·Ç³£¸Ðл£¡£¡£¡ 12-27 00:08
zap65535(½ð±Ò+3,VIP+0):ÖúÈËΪÀÖ 12-27 01:58
|
ϸ°ûϵºÍ˲ʱתȾ¡ª¡ªCOS-7ϸ°ûϵά³ÖÔÚ¼ÓÈë̥ţѪÇåºÍ2mM¹È°±õ£°·µÄDulbecco ¸ÄÁ¼ EagleµÄÅàÑø»ùÖУ¬ÎªÁËתȾ£¬60%-80%µÄÈÚºÏϸ°û°´ÕÕ˵Ã÷ÊéÓÃLipofectAMINE (Invitrogen)תȾ£¬24СʱºóÊÕ»ñϸ°û£¬Ã¿ÖÖÑùÆ··Ö×°³É2¸öС¹Ü£¬·Ö±ð×öÃâÒß³ÁµíʵÑéºÍDAG»îÐԲⶨ¡£J-HM1-2.2ϸ°ûϵÊÇÓÉJurkatϸ°ûϵÖÐÈËÀàÑÇÐÍ1¶¾Þ¦¼îÊÜÌåÎȶ¨×ªÈ¾²úÉú£¨29£©¡£²úÉúµÄϸ°û±£³ÖÔÚ¼ÓÓÐ10%µḀ̈ţѪÇåºÍ2mM¹È°±õ£°·µÄRPMI 1640ÅàÑø»ùÖС£ 20 g µÄ DNAÓÃ270VºÍ975µçÈݵÄÂö³åÆ÷µçת»¯¾¢(1.2 107)ϸ°ûÖУ¬Ï¸°ûѸËÙ×ªÒÆµ½30mlÉú³¤ÅàÑø»ùÖÐÅàÑø24hºó²â¶¨ |
3Â¥2009-12-26 21:23:21
lyh447lyh447
ÎÞ³æ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: -138.7
- Ìû×Ó: 33
- ÔÚÏß:
- ³æºÅ: 918144
- ×¢²á: 2009-12-02
zap65535(½ð±Ò+0,VIP+0):¿ÉÒÔȥרҵ°æ¿éÌáÎÊ 12-27 01:57
| ·Ç³£¸Ðл£¡£¡£¡ÎÒÏëÓÃDGK-IV»ùÒòתȾÐļ¡Ï¸°û£¬²»ÖªµÀÕâλÅóÓÑÄܲ»ÄÜÔÚÕâ·½ÃæÖ¸µãһϣ¡£¡£¡±¾È˷dz£¸Ðл£¡£¡£¡ÄãÄܸøÎÒ»ØÌû£¬ÎÒÏàÐÅÎÒÃÇÊÇÓÐÔµµÄ£¡£¡£¡ |
4Â¥2009-12-27 00:12:18
sophia622
ľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1794.4
- ºì»¨: 1
- Ìû×Ó: 207
- ÔÚÏß: 28.6Сʱ
- ³æºÅ: 490611
- ×¢²á: 2008-01-03
- ÐÔ±ð: MM
- רҵ: ÉúÎﻯѧ
5Â¥2009-12-27 11:56:52
lyh447lyh447
ÎÞ³æ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: -138.7
- Ìû×Ó: 33
- ÔÚÏß:
- ³æºÅ: 918144
- ×¢²á: 2009-12-02
6Â¥2009-12-27 12:04:08














»Ø¸´´ËÂ¥